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Integrated continuous manufacturing offers great productivity advantages over the traditional fed-batch and 
therefore reduces production scale, facility footprint, and manufacturing costs.  Recent advancement in process 
and control technologies, equipment capabilities, and automation has paved the way for the biopharmaceutical 
industry to start adapting processes to continuous manufacturing for clinical and commercial products.  As we 
shift to these approaches, strategies and methodologies need to be established for introducing and developing 
continuous processes.  Ideally, a platform continuous process would be established. Aspects to consider for the 
platform include cell line, cell culture media, process equipment, and a framework of process parameters that 
are all tailored to fit continuous manufacturing.  Once established, the platform will allow shortened process 
development timelines, easy adaptation from one molecule to another, and improved efficiency of tech transfer 
into GMP manufacturing.  
 
For processes that are in late clinical development or in commercial manufacturing, with an existing fed-batch 
cell culture process, a process conversion strategy should be established. In these cases, existing development 
and characterization of the original fed-batch process can be leveraged for unit operations that are constant or 
similar from fed-batch to continuous.  The platform continuous process can be adapted, and toolboxes can be 
created during the product-specific process development.  
 
The ultimate goal is to deliver robust continuous cell culture manufacturing processes with faster timeline and 
less development cost. This presentation will illustrate the strategy taken in Novartis with a few case studies.  
 
 
 
